Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Tolerability of CTP-730 in Healthy Adults
NCT02404922Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Mar 2015
- Primary completion
- Jun 2015
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CTP-730 in Inflammatory Disorders, psoriasis and psoriatic arthritis (PsA) (3 arms), sponsored by Concert Pharmaceuticals. Primary endpoints: Pharmacokinetic Profile at 96 hours and Number of Participants with Adverse Events at 24 hours. Started Mar 2015; status: completed.
02
Drugs
CTP-730
03
Conditions
Inflammatory Disorderspsoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02404922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02404922.